Engflag
Advertisements

Acatar Acti-Tabs

Quick links to important sections

Acatar Acti-Tabs

Acatar Acti-Tabs_EN
Advertisements
Advertisements

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Acatar Acti-Tabs

Quick Facts

Property Description
Active Ingredients Pseudoephedrine hydrochloride, Triprolidine hydrochloride
Form Tablet (Oral route)
Pharmacological Class Antihistamine/Decongestant Combination
Common Purpose Symptomatic relief of nasal congestion and rhinorrhea
Origin Synthetic compounds

What Type of Medicine is Acatar Acti-Tabs?

Acatar Acti-Tabs is a proprietary oral medication presented as a tablet, classified within the therapeutic category of an Antihistamine/Decongestant Combination. This product is a fixed-dose combination drug, meaning it contains two distinct active ingredients delivered simultaneously. Due to its intended oral route, the medicine exerts a systemic effect throughout the body, providing comprehensive relief to congestion within the nasal and paranasal sinuses. This approach is intended for the temporary and supportive management of upper respiratory discomfort.

Composition: Active Ingredients and Therapeutic Class

The formulation is defined by its two primary active ingredients: Pseudoephedrine hydrochloride and Triprolidine hydrochloride. Pseudoephedrine is categorized as a sympathomimetic amine, primarily functioning as a systemic nasal decongestant. Triprolidine is classified as a first-generation H1-receptor antagonist (antihistamine). This two-component structure is indicated for the management of symptoms stemming from both allergic reactions and the common cold. Both compounds are synthetic in origin and are prepared in a solid tablet form.

General Purpose and Benefit

The core general purpose of Acatar Acti-Tabs is the symptomatic treatment of distress commonly associated with rhinitis and upper respiratory symptoms. The combined action provides integrated benefit: the decongestant component works to relieve the physical discomfort of nasal congestion, while the antihistamine component minimizes irritative signs, such as sneezing and excessive rhinorrhea. This integrated approach is typically sought when a patient requires simultaneous relief from both swelling and fluid production, a common scenario in cases of seasonal allergic rhinitis.

Regulatory References

  1. NIH LiverTox Triprolidine Monograph
Advertisements

What side effects are possible with Acatar Acti-Tabs?

Possible side effects and safety information

The safety profile of Acatar Acti-Tabs, a fixed-dose combination of pseudoephedrine and triprolidine, is documented in official regulatory sources according to frequency and body system classifications.

Frequency-Classified Adverse Reactions

The most commonly reported adverse reaction, classified as Very Common, is drowsiness or sedation, stemming from the antihistamine component. Common effects, which may affect up to 1 in 10 people, include insomnia, nervousness, dry mouth, and headache. Adverse reactions classified as Rare include severe events such as hypersensitivity reactions and palpitations. Effects with Not Known frequency, meaning their rate cannot be estimated from available data, include serious vascular events.

Serious Safety Considerations and Restrictions

The official label documents specific safety concerns that require attention. Serious adverse reactions reported in regulatory sources include rare events such as cerebrovascular events (including stroke and Posterior Reversible Encephalopathy Syndrome (PRES)), ischaemic colitis, and severe skin reactions. These are often associated with the sympathomimetic component, pseudoephedrine.

Due to the documented risks, the medicine is contraindicated in patients with pre-existing conditions such as severe or uncontrolled hypertension, severe coronary artery disease, and severe renal failure. Safety caution is explicitly required for other conditions, including closed-angle glaucoma, prostatic enlargement, and hyperthyroidism.

Population-Specific Safety Notes

Safety data specifies that older adults may have an increased sensitivity to the central nervous system effects, leading to a higher potential for confusion or urinary retention. Furthermore, the medicine is intended only for short-term use as defined in regulatory texts.

Advertisements

Overdose and Emergency Response

The regulatory information for Acatar Acti-Tabs overdose describes a profile based on documented manifestations in two primary physiological systems: the Central Nervous System (CNS) and the cardiovascular system.

Documented Manifestations

CNS signs reported in overdose may include both stimulatory effects, such as agitation, confusion, restlessness, and convulsions or seizures, and depressive effects, including drowsiness, weakness, and inco-ordination. Cardiovascular presentations include hypertension, palpitation, tachycardia, and irregular heartbeat. Other documented symptoms are respiratory depression and difficulty with micturition (urinary retention).

Severe Outcomes and Emergency Response

Official labeling documents the potential for severe or life-threatening outcomes, specifically Posterior Reversible Encephalopathy Syndrome (PRES), Reversible Cerebral Vasoconstriction Syndrome (RCVS), and cardiovascular collapse. Due to the risk of such severe events, regulatory authorities mandate that emergency medical attention must be sought at once for any suspected overdose.

Immediate medical assistance is required if serious symptoms, such as trouble breathing, seizures, or passing out, occur. If a patient experiences a sudden, severe headache, confusion, or visual changes—symptoms linked to PRES or RCVS—the medicine must be discontinued immediately, and urgent medical help is required. Management consists of providing symptomatic and supportive treatment, as described in regulatory documents. Official guidance also notes that children and elderly adults may exhibit increased sensitivity, potentially showing heightened excitation or confusion in an overdose scenario.

Advertisements

Therapeutic Uses of Acatar Acti-Tabs

What Acatar Acti-Tabs treats: main uses and benefits

This medication is commonly used to provide temporary symptomatic relief for acute upper respiratory conditions, such as the common cold, flu-like symptoms, and allergic reactions. The product is relevant across domains where additional symptomatic support is needed.

The medicine is applied in scenarios where symptoms create noticeable physiological strain, primarily helping to ease nasal congestion, sinus pressure, runny nose, sneezing, and nasal irritation. By targeting this cluster of symptoms, the treatment supports patients during episodes of heightened discomfort.

It is relevant for easing symptoms specifically related to a blocked or stuffy nose and the associated sinus pressure. It is commonly used to help with congestion, providing supportive relief that generally contributes to clearer breathing through the nose. This approach assists with maintaining functional stability when symptoms interfere with routine activities.

Quick Fact: Relief for Nasal Congestion
Primary Use Context: Often used during phases when cold or allergy symptoms become more noticeable and short-term symptomatic assistance is needed to ease nasal stuffiness.
Advertisements

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Acatar Acti-Tabs

Category Official Regulatory Statement
Populations for whom use is allowed: Adults and adolescents 12 years of age and over (for the tablet formulation).
Populations for whom use is not recommended: Use is generally not recommended during Pregnancy or Lactation.
Populations for whom use is contraindicated: Children under 12 years of age are prohibited from using this formulation.

Condition-Specific Eligibility Rules

The medicine is contraindicated for patients with specific health conditions, including severe hypertension or severe coronary artery disease. Other absolute prohibitions include patients with closed-angle glaucoma, hyperthyroidism (overactive thyroid), diabetes mellitus, and phaeochromocytoma. The medication is also strictly prohibited for individuals who have taken a Monoamine Oxidase Inhibitor (MAOI) within the preceding 14 days.

Eligibility-Related Restrictions

Regulatory labeling requires caution for several groups. This includes older adults (geriatrics) and patients with pre-existing conditions such as mild to moderate renal impairment or severe hepatic impairment (liver problems). Caution is also advised for patients with prostatic enlargement or certain chronic breathing problems.

Connection to the overall eligibility profile:

Official regulatory documents define the eligible population for the tablet formulation as adults and adolescents 12 years and older. Use is strictly forbidden (contraindicated) for children under 12 and for specific cardiovascular and metabolic conditions. For all other populations with organ impairment or age-related sensitivities, the label imposes explicit restrictions, ensuring use adheres to defined conditional boundaries.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines documented interactions for Acatar Acti-Tabs (Pseudoephedrine/Triprolidine) based strictly on authoritative regulatory information. The interaction profile is structured around pharmacodynamic risk, high-risk prohibition, and pharmacokinetic modification.

High-Risk and Contraindicated Combinations

The co-administration of Acatar Acti-Tabs with Monoamine Oxidase Inhibitors (MAOIs) is strictly contraindicated. This combination carries a significant risk of severe, potentially life-threatening adverse reactions, including hypertensive crisis. Treatment with Acatar Acti-Tabs must not be initiated until at least 14 days have passed after discontinuing MAOI therapy.

Pharmacodynamic Interactions

Interacting Category Mechanism/Constraint
CNS Depressants & Alcohol May lead to additive CNS depression, increasing sedation and drowsiness due to the triprolidine component. Use must be avoided or managed with caution.
Sympathomimetic Agents May result in additive cardiovascular effects (e.g., increased blood pressure, heart rate) due to the pseudoephedrine component.
Anticholinergic Drugs May lead to additive anticholinergic effects (e.g., dry mouth, blurred vision) due to the triprolidine component.

Pharmacokinetic Modification

Interaction risk exists with agents that modify urine pH. Urine alkalinizers may decrease the renal elimination of pseudoephedrine, potentially increasing its systemic concentration and duration of exposure. Conversely, urine acidifiers may increase pseudoephedrine elimination, potentially reducing its effectiveness.

Advertisements

Mechanism of Action

How Acatar Acti-Tabs Works

The action of this fixed-dose combination product is governed by two complementary mechanistic domains that modulate distinct systems influencing local vascular and secretory physiology.

Sympathetic Modulation and Vascular Tone Control

This domain describes how the decongestant component engages the Adrenergic Pathway by acting as an agonist at alpha1-adrenoceptors and inhibiting the Noradrenaline Transporter (NET). This molecular action initiates a signaling cascade that triggers vasoconstriction in the nasal mucosa, which is the mechanism used to decrease tissue volume and local hyperemia.

Histaminergic Blockade and Secretory Pathway Interruption

This domain explains how the antihistamine component functions through competitive antagonism at the Histamine H1 Receptor. By blocking this key inflammatory mediator, the mechanism interrupts the histamine-driven increases in capillary permeability and sensory nerve firing, resulting in decreased fluid transudation and suppressed afferent nerve signaling.

Complementary Dual-System Action

This mechanistic principle highlights the synergy achieved by simultaneously modulating the autonomic control of local blood flow and the histamine-mediated secretory response. This combined action addresses two separate physiological drivers of the condition, leading to coordinated modulation of the vascular and secretory pathways in the upper respiratory mucosa.

Advertisements

Dosage and Administration Information

How to use Acatar Acti-Tabs — Administration Guidelines

The use of Acatar Acti-Tabs is governed by a defined protocol that specifies the method, frequency, and maximum daily limit for administration.

Administration Scope

Feature Guideline
Route of administration Oral route (taken by mouth).
Dosing schedule One tablet (60 mg Pseudoephedrine/2.5 mg Triprolidine) per dose.
Maximum Recommended Dose Not to exceed four tablets within a 24-hour period.
Frequency and timing Dose may be repeated every 4 to 6 hours as needed.
Timing in relation to meals May be taken with food to minimize stomach upset.
Preparation requirements None specified; the product is an immediate-release tablet form.
Age-group administration rules Authorized for patients 12 years of age and older; restricted in children under 12 years.
Missed-dose rules The regimen is as-needed, with the next dose taken when required, respecting the 4-hour minimum interval.
Special procedural conditions Patients must avoid alcohol and concurrent use of other sympathomimetic agents.

Instruction Classifications (High-Level)

Classification Detail
Administration method type Oral.
Frequency pattern As-needed (P.R.N.) dosing within a fixed 4 to 6-hour interval.
Use-context constraints Intended for short-term use only; if symptoms persist beyond 7 days, a consultation is indicated.

Resulting Procedural Structure

Step sequence:

  • Ingest the specified dose of one tablet by mouth.
  • Repeat the dose only after an interval of at least 4 hours has passed.
  • Ensure that the total number of tablets taken does not surpass the four-tablet maximum within any 24-hour period.

Connection to the overall use protocol: The instructions establish a standardized oral administration protocol with a fixed dose and a specific minimum time interval between doses. This structure limits the maximum daily intake and defines the product solely for short-term, as-needed usage. The regimen must be followed precisely to adhere to the established parameters for this fixed-dose combination product.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Acatar Acti-Tabs

Evidence for Use in Seasonal Allergic Rhinitis

Research exploring the combination was studied for symptoms related to seasonal allergies and includes short-term Randomized Controlled Trials (RCTs) and subsequent meta-analyses. These studies were used in research exploring how symptoms change over time, focusing on populations of adults with confirmed allergies. The research examined patient-reported outcomes describing perceived discomfort, alongside physiological measurements used in studies examining symptom intensity.

The trials monitored symptom patterns in the observed populations during periods of increased symptom activity, typically over a very limited follow-up duration. Findings describe patterns observed in the studies related to changes in symptom intensity and nasal airflow. The evidence was studied for short-term symptom patterns associated with conditions characterized by fluctuating or episodic manifestations.

It is important to note that long-term effects are not fully established for this combination, as follow-up durations were limited in the key efficacy trials. Data for certain groups, such as individuals with coexisting medical conditions, remain insufficient. Research provides context but does not determine whether an individual will respond similarly, and the findings apply only to the specific populations studied under the research conditions.

Evidence for Use in Common Cold Symptoms

The research base for the combination was evaluated in studies for common cold symptoms, including numerous older trials and Systematic Reviews and Meta-analyses. This research examined temporary physiological imbalance related to upper respiratory symptoms, which included outcomes describing episodic or acute changes. The studies monitored the responses over defined time intervals, typically ranging from three to ten days after administration.

These studies explored changes in patient-reported severity for symptoms such as nasal obstruction and excessive fluid discharge. Findings indicate that research highlights changes measured during the study period, helping to contextualize how patients reported their experience during episodes where symptoms become more noticeable. Research has also examined study outcomes related to the active ingredients against either a placebo or the use of only a single active ingredient.

What Remains Unknown About the Research Evidence

The available evidence contributes to the broader evidence landscape but also reveals several research gaps. The comparative evidence is lacking in some areas, particularly concerning the role of the antihistamine component when used for a non-allergic common cold. Findings were observed in some studies that evaluated measured changes in individual symptoms.

Certainty remains low regarding the use of this combination in complex patient subsets. Research is ongoing in related fields, but the existing data show patterns related to temporary relief, and the evidence provides context but does not determine whether an individual will respond similarly.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Acatar Acti-Tabs (FAQ)

Q: How quickly should I expect Acatar Acti-Tabs to start working?

Official product information describes the relief of symptoms beginning approximately 15 to 30 minutes after the tablet is administered. This time frame provides context for when the effects may begin to be noticed.

Q: How long do the effects of Acatar Acti-Tabs typically last?

According to official regulatory documents, the effects of the combination product are generally described to last for a minimum of 4 hours. This duration is consistent with the recommended minimum time interval that must pass before an additional dose can be considered.

Q: Is it possible for Acatar Acti-Tabs to cause stomach upset?

Yes, official safety information lists upset stomach as a possible side effect of this medicine. Official guidance notes that the medicine may be taken with food, which can help minimize the chance of digestive discomfort.

Q: Can I crush or chew Acatar Acti-Tabs instead of swallowing them whole?

Official administration guidelines classify the product as an immediate-release tablet intended for the oral route. The directions for use do not include information on crushing, chewing, or altering the tablet. The immediate-release tablet is typically taken by swallowing it whole.

Q: What are the typical storage conditions for Acatar Acti-Tabs?

Official storage requirements state the product should be kept in its original packaging for protection from light and moisture. The temperature for storage should not exceed 25 C to maintain the product's quality and stability.

Q: Is Acatar Acti-Tabs considered a pain reliever?

No. Acatar Acti-Tabs is officially classified as an Antihistamine/Decongestant combination designed solely for the symptomatic relief of nasal and upper respiratory discomfort. It does not contain an active ingredient classified as a pain reliever (analgesic).

Q: Does Acatar Acti-Tabs treat the underlying cause or just the symptoms?

The medicine is officially described as a symptomatic treatment, meaning its purpose is to relieve temporary discomfort caused by symptoms like congestion and runny nose. Regulatory product information confirms the medicine does not cure or change the underlying condition.

Q: Are there any common misuses of Acatar Acti-Tabs that I should be aware of?

Regulatory safety information specifically warns against the inappropriate use of the product to intentionally make a child sleepy. Official labels also include warnings related to the central nervous system and heart function that are associated with exceeding the maximum recommended daily amount.

Q: Can Acatar Acti-Tabs affect my heart rate or blood pressure?

Yes, due to the decongestant component (pseudoephedrine), the medication may affect heart rate (tachycardia) and blood pressure (hypertension). Official sources note that the product is contraindicated for use in patients with pre-existing severe or uncontrolled cardiovascular disease.

Q: What common supplements or vitamins might interact with Acatar Acti-Tabs?

The official interaction documents focus on prescription medicines, but regulatory advice states that a healthcare provider should be informed about all concurrent medications. This includes any vitamins or herbal products.

Q: Is it safe to drink coffee or caffeine while taking Acatar Acti-Tabs?

Regulatory documents indicate a need for caution when the medicine is co-administered with caffeine or coffee. Both caffeine and the decongestant component may stimulate the body and increase the risk of elevated blood pressure and heart rate.

Q: Can individuals who are lactose intolerant take Acatar Acti-Tabs?

No. Official ingredient lists confirm the tablet formulation contains lactose as a non-active ingredient (excipient). Individuals with lactose intolerance may wish to note this component when reviewing the product ingredients.

Q: Where can I find the official patient information leaflet for Acatar Acti-Tabs?

The most current and comprehensive patient information is contained in the official regulatory labeling, such as the Patient Information Leaflet or Summary of Product Characteristics. This documentation is available through the national medicines agencies or can be obtained from the dispensing pharmacist.

Q: Is Acatar Acti-Tabs ever used for symptoms other than its main indication?

Official labeling defines the purpose of the medicine as the symptomatic relief of nasal congestion, runny nose, and sneezing associated with colds, flu, and allergic rhinitis. Official labeling focuses exclusively on the purpose defined in the primary regulatory approval.

Q: Do I need to eat food when I take Acatar Acti-Tabs?

No, official regulatory guidelines state the medicine may be taken with food, but food is not a requirement for its administration. It is generally noted that taking the tablet with food can help minimize the chance of stomach upset.

Q: Are there any specific activities or machines I should avoid while using Acatar Acti-Tabs?

Due to the risk of drowsiness or dizziness, official warnings advise caution regarding activities that require mental alertness. Official warnings specify that driving or operating hazardous machinery should be avoided until an individual knows how the medicine affects their ability to remain alert.

Q: Is there a risk of becoming dependent on Acatar Acti-Tabs?

The active ingredients are not classified as controlled substances associated with a high physical dependence risk. Regulatory controls on the decongestant component reflect a history of potential misuse that may be associated with psychological dependence.

Q: Why is a pharmacist required to supervise the purchase of Acatar Acti-Tabs in some regions?

The requirement is due to the classification of one active ingredient, pseudoephedrine, as a controlled precursor substance in various regions. This control is mandated by government regulations and necessitates sale supervision by a pharmacist to ensure compliance.

Q: Are there any known interactions between Acatar Acti-Tabs and herbal teas?

Official documents advise informing a healthcare provider about the use of any herbal products, including teas. The possibility of interaction with the active ingredients may exist, and it is best to provide full information about all substances being consumed.

Q: What information is legally required to be on the Acatar Acti-Tabs packaging?

Government regulations mandate that packaging clearly display essential safety and use information. This includes the active ingredients, intended use, dosage instructions, contraindications (prohibitions), side effects, lot number, and the expiration date.

Q: Are Acatar Acti-Tabs approved for use during pregnancy, according to official sources?

Official regulatory documentation defines the product as generally not recommended during pregnancy or lactation due to limited available data. The product labeling recommends caution and case-by-case evaluation.

Q: Is there a specific age limit for purchasing Acatar Acti-Tabs?

Official regulations define the medicine for use by individuals 12 years of age and older. Separate regulations regarding the sale of products containing the decongestant component may impose additional local purchase restrictions, which vary by location.

Q: What happens to Acatar Acti-Tabs inside the body after it's swallowed?

After swallowing, the medicine is absorbed from the digestive system and distributed throughout the body. The active components begin to exert their systemic effect by modulating local vascular tone (the decongestant) and blocking histamine receptors (the antihistamine).

Q: Is it safe to use Acatar Acti-Tabs while recovering from a minor surgery?

Regulatory safety guidance specifies that a doctor or surgeon should be informed if this medicine has been taken prior to any planned surgery or medical tests. This is due to the potential for the ingredients to interact with certain anesthetic agents.

Q: Is dizziness a temporary side effect of Acatar Acti-Tabs?

Dizziness is listed in official documents as a potential side effect of the combination product. Side effects are generally expected to resolve once the medicine is discontinued. Individuals are advised to be aware of how the medicine affects them.

Advertisements

How should Acatar Acti-Tabs be stored and disposed of?

How to Store and Dispose of Acatar Acti-Tabs?

The official storage requirements for this medicine are designed to maintain product quality and safety.

Storage Requirements

  • Temperature: Store the product at a temperature that does not exceed 25 C.
  • Protection: Keep the medicine in its original blister packaging to protect it from moisture.
  • Safety: Always store Acatar Acti-Tabs out of the sight and reach of children.
  • Stability: Do not use the tablets after the expiration date printed on the carton and blister packaging.

Disposal Instructions

When the medicine is no longer needed, it must be disposed of properly to avoid environmental contamination. Do not dispose of Acatar Acti-Tabs via household waste or by pouring it down the drain or into wastewater. To ensure proper disposal, consult your pharmacist for instructions on how to discard unused or expired medicines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Acatar Acti-Tabs found in:

A-Z Index: